CompletedNCT01948024
Asenapine Brand and Generic Formulations Compared in Schizophrenia or Bipolarity
About this title
Read the official source — NCT01948024Medication studyAges 18–80United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 80 years.
- Listed locations
- Little Rock and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateJuly 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 65
- Sponsor
- Sun Pharmaceutical Industries Limited
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 80 Years
- Official registry ID
- NCT01948024
- Official title
Show the full official title
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · Costa Mesa · Garden Grove
4 more locations
- Leesburg
- Miami
- Atlanta
- Charlotte
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Sun Pharmaceutical Industries Limited, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SAPHRIS and Asenapine.
Who was this study for?
Listed age limits: 18 years to 80 years.
